GONAL-f 900 IU (66 mcg) pen

  • Name:

    GONAL-f 900 IU (66 mcg) pen

  • Company:
    info
  • Active Ingredients:

    Follitropin alpha

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 18/09/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 17/9/2018

Click on this link to Download PDF directly

Merck

Merck

Company Products

Medicine NameActive Ingredients
Medicine Name Campral EC Active Ingredients Acamprosate Calcium
Medicine Name Cardicor 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg film-coated tablets Active Ingredients Bisoprolol Fumarate
Medicine Name Cetrotide 0.25mg powder and solvent for solution for injection Active Ingredients cetrorelix acetate
Medicine Name Crinone 8% progesterone vaginal gel Active Ingredients Progesterone
Medicine Name Emcor Active Ingredients Bisoprolol Fumarate
Medicine Name Erbitux 5mg/ml solution for infusion Active Ingredients cetuximab
Medicine Name Glucophage 1000mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name Glucophage 500mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name Glucophage 850mg film-coated tablets Active Ingredients Metformin Hydrochloride
Medicine Name GONAL-f 1050 IU (77 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 300IU (22 mcg) pen Active Ingredients Follitropin alpha
Medicine Name GONAL-f 450 IU (33 mcg) pen Active Ingredients Follitropin alpha
Medicine Name GONAL-f 450 IU (33 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 75 IU (5.5 micrograms) Active Ingredients Follitropin alpha
Medicine Name GONAL-f 900 IU (66 mcg) pen Active Ingredients Follitropin alpha
Medicine Name Luveris 75 IU Active Ingredients Lutropin alfa
Medicine Name MAVENCLAD 10 mg Tablets Active Ingredients Cladribine
Medicine Name Ovitrelle 250 micrograms/0.5 ml pre-filled pen Active Ingredients Choriogonadotropin alfa
Medicine Name Pergoveris (900 IU + 450 IU)/1.44 mL solution for injection in pre-filled pen Active Ingredients follitropin alfa, Lutropin alfa
Medicine Name Praxilene Active Ingredients Naftidrofuryl Hydrogen Oxalate
Medicine Name Rebif 22 mcg Solution for Injection in Cartridge Active Ingredients Interferon beta-1a
Medicine Name Rebif 22 mcg Solution for Injection in Pre-Filled Pen Active Ingredients Interferon beta-1a
Medicine Name Rebif 22 mcg Solution for Injection in Pre-Filled Syringe Active Ingredients Interferon beta-1a
Medicine Name Rebif 44 mcg Solution for Injection in Cartridge Active Ingredients Interferon beta-1a
Medicine Name Rebif 44 mcg Solution for Injection in Pre-Filled Pen Active Ingredients Interferon beta-1a
1 - 0 of 32 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 18 September 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 17 September 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 26 April 2018 Ed-HCP

Reasons for updating

  • Add New Doc

Updated on 11 May 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 11 May 2017 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 - Undesirable effects

Thromboembolism may occur very rarely (see section 4.4).

 

 

Vascular disorders

Very rare:       Thomboembolism (both in association with and separate from OHSS)

Updated on 10 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 10 May 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change of distributor details

Updated on 20 February 2017 PIL

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to other sources of information section

Updated on 16 December 2016 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable effects - how to report a side effect - was updated with the addition of Malta. Internal Ref: TW1230178.

Updated on 2 August 2016 PIL

Reasons for updating

  • Change to further information section

Updated on 8 July 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 29 May 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8 Undesirable effects

 

Ireland

HPRA Pharmacovigilance

Earlsfort Terrace

IRL - Dublin 2

Tel: +353 1 6764971

Fax: +353 1 6762517

Website: www.hpra.ie

e-mail: medsafety@hpra.ie

Updated on 30 July 2014 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 12 May 2014 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Minor editorial changes, including information on the reporting of adverse reactions in section 4.8.

 

Date change in Section 10

Updated on 14 April 2014 PIL

Reasons for updating

  • Change of distributor details

Updated on 24 October 2012 PIL

Reasons for updating

  • Change of distributor details

Updated on 30 July 2012 PIL

Reasons for updating

  • Change of distributor details

Updated on 10 April 2012 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 7 September 2011 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections have been updated:

 

3. PHARMACEUTICAL FORM

Solution for injection in pre-filled pen.

....

4. CLINICAL PARTICULARS

.....

4.2 Posology and method of administration

Treatment with GONAL-f should be initiated under the supervision of a physician experienced in the treatment of fertility disorders.

Patients must be provided with the correct number of pens for their treatment course and educated to use the proper injection techniques.

Posology

The dose recommendations given....

Method of administration

.......

For instructions on the administration with the pre-filled pen, see section 6.6 and the

 

“Instructions for Use”.

 

4.4 Special warnings and precautions for use

........

Thromboembolic events

In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for

 

thromboembolic events, such as personal or family history, treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events. In these women, the benefits of gonadotropin administration need to be weighed against the risks. It should be noted however that pregnancy itself as well as OHSS also carry an increased risk of thromboembolic events.

 

......

4.8 Undesirable effects

.....

Mild or moderate ovarian hyperstimulation syndrome (OHSS)

 

has been commonly reported and should be considered as an intrinsic risk of the stimulation procedure. Severe OHSS is uncommon (see section 4.4).

 

....

6.5 Nature and contents of container

GONAL-f 300 IU/0.5ml PEN

.....

Pack of one pre-filled pen and

 

8 needles to be used with the pen for administration

 

GONAL-f 450 IU/0.5ml PEN

.....

Pack of one pre-filled pen and

 

12 needles to be used with the pen for administration

 

GONAL-f 900 IU/0.5ml PEN

.....

Pack of one pre-filled pen and

 

20 needles to be used with the pen for administration

 

6.6 Special precautions for disposal and other handling

See the

 

“Instructions for Use”.

 

.....

10. DATE OF REVISION OF THE TEXT

May 2011

Updated on 10 November 2010 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Date of Renewal corrected to:

Date of last renewal: 20 October 2010

Updated on 13 August 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Changes to SPC are widespread throughout document as result of MA Renewal. SPC is in compliance with QRD template.

Updated on 28 October 2009 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change to section 7

From:

Serono Europe Ltd.

56 Marsh Wall

London E14 9TP

United Kingdom


To:

Merck Serono Europe Ltd.

56 Marsh Wall

London E14 9TP

United Kingdom

Updated on 3 September 2009 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Following changes apply:

4.2     Posology and method of administration



It is advised to adhere to the recommended starting doses indicated below.

Comparative clinical studies have shown that on average patients require a lower cumulative dosage and shorter treatment duration with GONAL-f compared with urinary FSH. Therefore, it is considered appropriate to give a lower total dosage of GONAL-f than generally used for urinary FSH, not only in order to optimise follicular development but also to minimise the risk of unwanted ovarian hyperstimulation. See section 5.1



5.1       Pharmacodynamic properties

In clinical studies comparing r-hFSH (follitropin alfa) and urinary FSH in assisted reproduction technologies (see table below) and in ovulation induction, GONAL-f was more potent than urinary FSH in terms of a lower total dose and a shorter treatment period needed to trigger follicular maturation.

In assisted reproduction technologies, GONAL-f at a lower total dose and shorter treatment period than urinary FSH, resulted in a higher number of oocytes retrieved when compared to urinary FSH.

 

Table: Results of study GF 8407 (randomised parallel group study comparing  efficacy and safety of Gonal-f with u-FSH in assisted reproduction technologies)



 

GONAL-f
(n = 130)

u-FSH
(n = 116)

No. of oocytes retrieved

11.0 ± 5.9

8.8 ± 4.8

Days of FSH stimulation required

11.7 ± 1.9

14.5 ± 3.3

Total dose of FSH required (no. of FSH 75 IU ampoules)

27.6 ± 10.2

40.7 ± 13.6

Need to increase the dosage (%)

56.2

85.3


Differences between the 2 groups were statistically significant (p<0.05) for all criteria listed.

Updated on 28 May 2008 SmPC

Reasons for updating

  • Change to section 6.4 - Special precautions for storage

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 6.4 changed from:

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C). Do not freeze.
Within its shelf-life, the product may be stored at or below 25°C for up to 28 days and must be discarded if not used.
Store in the original package in order to protect from light.

To:

6.4 Special precautions for storage

Store in a refrigerator (2°C - 8°C). Do not freeze.
Within its shelf life, the product may be stored at or below 25°C for up to 3 months without being refrigerated again and must be discarded if it has not been used after 3 months.
Store in the original package in order to protect from light.
For in-use storage conditions, see section 6.3.

Updated on 17 August 2006 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.3 - Shelf life
  • Change to section 6.5 - Nature and contents of container
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 2 Qualitative and Quantitative Composition: Text amended to include:Excipients: 90 mg sucrose, 1.665 mg disodium phosphate dihydrate, 0.675 mg sodium dihydrogen phosphate monohydrate, 0.15 mg methionine, 4.5 mg m‑cresol, 0.15 mg poloxamer 188.’

 

‘For a full list of excipients, see section 6.1.’

 

Section 3 Pharmaceutical Form: pH added.

 

Section 4.4 Special warnings and precautions for use: The following warnings have been added:

 

‘Patients with porphyria or a family history of porphyria should be closely monitored during treatment with GONAL-f. Deterioration or a first appearance of this condition may require cessation of treatment.’

 

‘GONAL-f contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-free”.’

 

‘Very rarely, severe OHSS may be complicated by pulmonary embolism, ischemic stroke and myocardial infarction.’

 

Section 4.8 Undesirable Effects: The listing of adverse events reported is updated presented by body systems. Adverse events added include:

 

Treatment in women

Very rare:

Immune system disorders: Urticaria, oedema, difficulty breathing. Serious cases of allergic reactions including anaphylactic reactions have also been reported.

Respiratory, thoracic and mediastinal disorders: exacerbation or worsening of asthma.

Treatment in men

Common:

Reproductive system and breast disorders: Varicocele

Very common:

General disorders and administration site conditions: Mild to severe injection site reaction (pain, redness, bruising, swelling and/or irritation at the site of injection)

 

The following paragraph has been added ‘Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.’

 

Section 5.3 Preclinical safety data: The first paragraph has been deleted and replaced with ‘Non-clinical data reveal no special hazard for humans based on conventional studies of single and repeated dose toxicity and genotoxicity additional to that already stated in other sections of the SPC.’

 

Section 6.3 Shelf life: The last sentence ‘After first use: 28 days (within the 2 year shelf-life) has been amended to ‘After first use: 28 days (within the shelf-life)’.

 

Section 6.5 Nature and contents of container:  The first sentence has been amended as follows: 1.5 ml of solution for injection in 3 ml cartridge (Type I glass), with a plunger stopper (halobutyl rubber) and an aluminium crimp cap with a black rubber inlay.

 

Section 9 Date of First Authorisation / Renewal of Authorisation: Date of renewal has been added.

 

Section 10 Date of Revision of the Text: Amended to July 2006.

 

 

Updated on 1 November 2004 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 6 August 2004 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 19 May 2004 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)